Rheumatology 1
HLA subtype positive in 92% of White persons with axial spondyloarthritis
HLA-B27 (accept B27)
Recommended first-line urate-lowering therapy for gout
Allopurinol
Drug therapy for all patients with SLE without contraindications
Hydroxychloroquine
Testing for all patients with metastatic NSCLC to guide therapy
PD-L1 expression
Non-germ cell tumor diagnosed based on elevated alpha fetoprotein level without a tissue biopsy
Hepatocellular carcinoma (accept HCC)
Autoimmune condition in which most patients have positive anti–cyclic citrullinated peptide antibodies
Rheumatoid arthritis
Treatment of acute gout flares
NSAIDs, colchicine, or glucocorticoids
Most specific antibody test for diagnosis of SLE
Anti-Smith antibody
Treatment of metastatic NSCLC positive for PD-L1
Pembrolizumab
Herpesvirus implicated in nasopharyngeal carcinoma and certain forms of lymphoma
Epstein-Barr virus (accept EBV, human herpes virus 4, or HHV-4)
Condition characterized by objective keratoconjunctivitis sicca and xerostomia with autoantibodies
Sjögren syndrome
Prophylaxis effective for most patients when initiating urate-lowering treatment
Colchicine
Indications for kidney biopsy in SLE
Abnormal proteinuria, active urinary sediment, and/or elevated creatinine level
Metastatic NSCLC treatment in absence of driver alterations
Platinum-based chemotherapy and/or immunotherapy
Solid organ tumor for which the Robson staging system was historically used
Renal cell carcinoma (accept RCC, renal cancer, or kidney cancer)
Periorbital skin finding pathognomonic for dermatomyositis
Heliotrope eruption (accept heliotrope rash or heliotrope sign)
IV treatment of recurrent and/or tophaceous gout
Pegloticase
Antibodies associated with greatest risk for thrombosis in SLE
Lupus anticoagulant, anti–β2 glycoprotein, anticardiolipin
Checkpoint inhibitor toxicity
Autoimmune diseases
Stage of colon cancer with the best demonstrated survival benefit for adjuvant chemotherapy
Stage III (node-positive)
Antibodies against this nuclear enzyme put scleroderma patients at highest risk of cancer within 3 years of disease onset
RNA pol III (RNA polymerase III)
Coadministration with colchicine reduces hepatic catabolism and could lead to colchicine overdose
CYP3A4 inhibitors (such as clarithromycin)
Indications for high-dose glucocorticoids in SLE
Profound cytopenias, class III/IV nephritis, seizures, psychosis
Molecular analysis for all metastatic colorectal cancer
KRAS, NRAS, BRAF, mismatch repair genes; HER2 amplification status
Adjuvant chemotherapeutic that prolongs pancreatic cancer survival over gemcitabine alone
Capecitabine